ProMining Therapeutics, Ltd. Announced a Collaboration With Roche for the Discovery of Small Molecule Therapeutics for the Treatment of Type 2 Diabetes Using ProMining’s CavitIIRx Platform Technology
JERUSALEM, December 17, 2012 /PRNewswire/ –
ProMining Therapeutics [http://www.prominingtherapeutics.com ], Ltd. today announced a
new collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) in the field of type 2 diabetes
mellitus. Under the terms of the agreement, ProMining Therapeutics will use its CavitIIRx
platform to develop small molecule therapeutics for treatment of type 2 diabetes mellitus
and will receive research based funding. Further details of the agreement were not
“We are pleased to have completed this agreement with Roche and are very excited by
the prospect of jointly delivering novel therapeutic oral small molecules to patients
suffering from type 2 diabetes mellitus. ProMining has developed novel technology for the
discovery of small molecules interfering in protein-protein interactions that are clearly
differentiated from conventional small molecule drugs. This partnership will enable
ProMining to expand the exploitation of this technology by combining with the impressive
global research and development capabilities and resources of Roche,” says Dr. Iris Alroy,
ProMining Therapeutics CEO.
About ProMining Therapeutics
ProMining Therapeutics, Ltd., based in Israel is a Van Leer Technology Ventures
Jerusalem and Pontifax portfolio company established in 2011 by Dr. Silvia Noiman, Dr.
Iris Alroy and Dr. Arnon Aharon and operating within the Van Leer incubator. The company
is a biopharmaceutical research and development company engaged in the discovery and
development of novel oral, small-molecule drugs for a variety of indications including:
cancer, inflammation, chronic pain, cardiovascular and viral diseases.
The Company has developed CavitIIRx, a proprietary drug discovery and development
platform, focused on SH3 domain-mediated protein-protein interactions, known to play a
major role in numerous disease mechanisms. ProMining’s approach includes integration of
state-of-the-art computational analysis tools and novel biological assays directed towards
identification of small molecules blocking SH3-partner interaction. These tools are
applied for a fast discovery and development of SH3-partner inhibitors of different
targets, thereby creating a substantial pipeline.
Within a year from its incorporation ProMining was able to identify protein-protein
interfering small molecules for its oncology project. The oncology project targets the
ArgBP2-PAK1 SH3 domain mediated interaction. ArgBP2 coordinates PI3K signaling of the
PI3K/Akt/Bcl2 pathway, which plays a detrimental role in many cancers.
Contact: Iris Alroy, Ph.D. CEO E-mail: firstname.lastname@example.org Phone: +972-52-3961013
SOURCE ProMining Therapeutics Ltd